On July 9, 2026, Jennifer E. Cook, serving as a director at BridgeBio Pharma, Inc. (NASDAQ: BBIO), finalized a substantial transaction involving the disposal of 148,589 shares of the company's common stock. The aggregate value of this divestment reached approximately $13.16 million. The execution of these shares occurred at prices fluctuating between $84.00 and $90.00 per unit. This specific sale was conducted in strict adherence to a Rule 10b5-1 sales plan, which Ms. Cook originally established on March 16, 2026. The timing of this transaction is notable given that BBIO was trading in close proximity to its 52-week high of $93.42. Over the preceding twelve-month period, the stock had generated a return of 85%.
According to analysis provided by InvestingPro, the current valuation of BBIO appears marginally elevated when measured against its Fair Value estimate. The platform further indicated that ten additional ProTips are available for BBIO, offering deeper insights into the company's financial stability and momentum metrics. On the identical date of the sale, Ms. Cook also engaged in a significant acquisition activity. She purchased 148,589 shares of BridgeBio Pharma common stock through the exercise of stock options. The total expenditure for these acquisitions was approximately $3.71 million. The exercise prices for these shares varied, ranging from $8.45 to $29.00 per share.
The specific options exercised comprised 19,000 shares with an exercise price of $8.45, 112,422 shares priced at $29.00, and 17,167 shares at $16.75. These options were subject to various vesting schedules, which were generally contingent upon Ms. Cook's continued service on the company's Board of Directors over multiple years. Following the completion of these transactions, Ms. Cook's direct holdings in BridgeBio Pharma common stock stood at 8,383 shares.
In broader corporate developments, BridgeBio Pharma disclosed a major capital event involving a $1 billion preferred equity investment. This investment was led by Sixth Street, with participation from HealthCare Royalty, a business unit of KKR. The instrument issued was a Series A Cumulative Convertible Participating Preferred Stock, which carries a 7.00% initial dividend. The terms also include conversion price premiums designated for future years. Concurrently, the company released post-hoc analyses regarding kidney function data for acoramidis in patients diagnosed with transthyretin amyloid cardiomyopathy. The data revealed an early, reversible dip in estimated glomerular filtration rate alongside a reduction in the urinary albumin to creatinine ratio.
Looking ahead, BridgeBio plans to present data from its Phase 3 study of oral infigratinib for achondroplasia at an upcoming congress. In related market movements, shares of both Alnylam Pharmaceuticals and BridgeBio Pharma experienced upward pressure following the failure of a rival drug in a late-stage trial for a nerve disease. Both companies hold approved treatments for this condition. On the analyst front, Mizuho adjusted its price target for BridgeBio Pharma downward from $106 to $96, citing balance sheet concerns. Despite this revision, Mizuho maintained an Outperform rating for the stock. These developments collectively provide investors with a comprehensive view of BridgeBio Pharma's financial activities, clinical progress, and market positioning.